Multicenter study of compliance and drop administration in glaucoma

Canadian Journal of Ophthalmology

Volumn 43, Issue 4, 2008, Pages 454-461

  Kholdebarin, Ramin ^a   Campbell, Robert J ^a   Jin, Ya Ping ^b   Buys, Yvonne M ^c   Beiko, George ^d   Birt, Catherine ^d   Damji, Karim ^d   Feldman, Frederick ^d   Lajaoie, Caroline ^d   Kulkarni, Sadhana ^d   Martow, Jeffery ^d   Sakamoto, Terence ^d   Spencer, Jon ^d   Trope, Graham E ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d NONE

Author keywords

Administration; Aged; Education; Glaucoma; Patient compliance; Prevalence; Topical

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS; TOPICAL AGENT;

ACCURACY; ADULT; AGED; ARTICLE; CANADA; CLINICAL PROTOCOL; CLINICAL TRIAL; EDUCATION; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; QUESTIONNAIRE;

EID: 49949099376     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I08-076     Document Type: Article

References (32)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7.
2. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
6. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2005;112:953-61.
7. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol 1984;19:2-5.
8. Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000;5:752-6.
9. Geyer O, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol 1995;79:376-9.
10. Campbell RJ, Trope GE, McIlraith I, Buys YM. Administration technique and compliance in topical drug therapy of glaucoma. Proceedings of the Canadian Ophthalmological Society Annual Meeting; June 21-24, 2006, Toronto, Ont.
11. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113:431-6.
12. Koucheki B, Nouri-Mahdavi K, Patel G, Gaasterland D, Caprioli J. Visual field changes after cataract extraction: the AGIS experience. Am J Ophthalmol 2004;138:1022-8.
13. Kharod BV, Johnson PB, Nesti HA, Rhee DJ. Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients. J Glaucoma 2006;15:244-7.
14. Lehto I. Side effects of topical treatment in pigmentary glaucoma. Acta Ophthalmologica 1992;70:225-7.
15. Bloch S, Rosenthal AR, Friedman L, Caldarolla P. Patient compliance in glaucoma. Br J Ophthalmol 1977;61:531-4.
16. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye 1998;12:234-6.
17. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986;101:515-23.
18. Busche S, Gramer E. Improved eyedrop administration and compliance in glaucoma patients. A clinical study. Klin Monatsbl Augenheilkd 1997;211:257-62.
19. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993;83:711-6.
20. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophthalmol 1983;67:46-9.
21. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6.
22. Spaeth GL. Visual loss in a glaucoma clinic. I. Sociological considerations. Invest Ophthalmol 1970;9:73-82.
23. Vincent PA. Patients' viewpoint of glaucoma therapy. Sight Sav Rev 1972;42:213-21.
24. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol 1983;28:252-8.
25. Kahook MY. Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives. Expert Rev Med Devices 2007;4:261-6.
26. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006;17:190-5.
27. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8.
28. Stack RR, McKellar MJ. Black eye drop bottle tips improve compliance. Clin Experiment Ophthalmol 2004;32:39-41.
29. Averns H, Hall J, Webley M. Role of Opticare eye drop delivery system in patients with rheumatoid arthritis. J Rheumatol 1999;26:2615-8.
30. Chang JS Jr., Lee DA, Petursson G, et al. The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure. J Ocul Pharmacol 1991;7:117-24.
31. Granstrom PA. Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy. Arch Ophthalmol 1985;103:529-31.
32. Gurwitz JH, Yeomans SM, Glynn RJ, Lewis BE, Levin R, Avorn J. Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. Med Care 1998;36:357-69.